Indium-111-capromab pendetide scans: An important test relevant to clinical decision making

Urology

Volumn 57, Issue 3, 2001, Pages 399-401

  Sartor, Oliver ^a,c   McLeod, David ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; EPITOPE; MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; HUMAN; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; SCINTISCANNING; SCORING SYSTEM; SHORT SURVEY;

EID: 0035123440     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)01084-0     Document Type: Editorial

References (9)

1. Immunoscintigraphy with indium-111-capromab pendetide; evaluation before definitive therapy in patients with prostate cancer
2. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy
3. 111 indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
4. Radiation therapy for a rising PSA level after radical prostatectomy
5. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy
6. In-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer
7. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
8. Focus on economics; program serves as model for teaching new technology